Dividend Center Best Dividend Stocks

Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison

Dividend Calculator Dividend Returns Comparison Dividend Calendar

My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors

Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

Follow Us

News Trending Portfolio

TOOLS

Top Insiders Stocks

Notification Center

Top Smart Score Stocks

STOCKS

Plans & Pricing

Dividend Center

Best Dividend Stocks

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Enterprise Solutions

Education

How To Use TipRanks

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Follow Us

Best Healthcare & Medical Stocks

Compare the best healthcare stocks, get the most updated comparison by key indicators and discover each stock’s price target as well as recommendations by top Wall Street experts.

Compare up to 10 stocks

Comparison Results

Name	Price	Price Change	Volume	Market Cap	Analyst Price Target	Analyst Consensus	Smart Score	Article	Follow
PFE Pfizer	$30.07	$0.8 (2.73%)	29.22M	$165.86B	xxxxxxxxxxxxx	7 Buy 11 Hold 0 Sell Moderate Buy
NVS Novartis	$116.95	$1.29 (1.12%)	924.95K	$229.51B	xxxxxxxxxxxxx	1 Buy 6 Hold 0 Sell Hold
JNJ Johnson & Johnson	$166.99	$1.47 (0.89%)	5.19M	$398.45B	xxxxxxxxxxxxx	6 Buy 8 Hold 0 Sell Moderate Buy
RHHBY Roche Holding	$39.21	$0.1 (0.26%)	1.86M	$253.42B	xxxxxxxxxxxxx	0 Buy 1 Hold 0 Sell Hold
ABT Abbott Laboratories	$117.63	$1.23 (1.06%)	3.64M	$202.52B	xxxxxxxxxxxxx	11 Buy 3 Hold 0 Sell Strong Buy
LLY Eli Lilly & Co	$923.54	$0.17 (0.02%)	1.76M	$877.92B	xxxxxxxxxxxxx	18 Buy 2 Hold 0 Sell Strong Buy
CVS CVS Health	$58.37	$0.39 (0.67%)	5.17M	$72.94B	xxxxxxxxxxxxx	7 Buy 8 Hold 0 Sell Moderate Buy
UNH UnitedHealth	$589.14	$3.08 (0.52%)	2.55M	$548.81B	xxxxxxxxxxxxx	21 Buy 0 Hold 0 Sell Strong Buy
TDOC Teladoc	$8.16	$0.07 (0.87%)	5.02M	$1.39B	xxxxxxxxxxxxx	5 Buy 13 Hold 0 Sell Moderate Buy

Performance Comparison

PFE

Pfizer

29.27

-2.50

-7.87%

NVS

Novartis

115.66

21.38

22.68%

JNJ

Johnson & Johnson

165.52

8.03

5.10%

RHHBY

Roche Holding

39.11

4.17

11.93%

ABT

Abbott Laboratories

116.40

17.46

17.65%

LLY

Eli Lilly & Co

923.71

356.24

62.78%

CVS

CVS Health

57.98

-10.05

-14.77%

UNH

UnitedHealth

594.32

113.85

23.70%

TDOC

Teladoc

8.09

-12.68

-61.05%

Compare the performance , dividend, and cannabis stocks. Go to the Stock Comparison tool to compare more stocks on key indicators.

Healthcare Stocks Latest News

J&J data presents ‘limited downside’ to CG Oncology, says Goldman Sachs

J&J data presents ‘limited downside’ to CG Oncology, says Goldman Sachs

Goldman Sachs keeps a Buy rating on CG Oncology (CGON) after Johnson & Johnson (JNJ) presented updated data...

9h ago

Novartis announces updated analysis from Phase III NATALEE trial

Novartis announces updated analysis from Phase III NATALEE trial

In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqal added to endocrine therapy shows...

14h ago

FDA Approval of EBGLYSS Boosts Eli Lilly’s (NYSE:LLY) Eczema Treatment Portfolio

FDA Approval of EBGLYSS Boosts Eli Lilly’s (NYSE:LLY) Eczema Treatment Portfolio

Eli Lilly and Co. ($LLY) announced that the U.S. Food and Drug Administration (FDA) had approved its atopic dermatitis...

15h ago

Johnson & Johnson announces interim data from SunRISe-4 study

Johnson & Johnson announces interim data from SunRISe-4 study

Johnson & Johnson announced interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational...

16h ago

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Basel, 16 September 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and...

20h ago

Eli Lilly and AbbVie: J.P. Morgan Selects the Top Large-Cap Pharma Stocks to Buy

Eli Lilly and AbbVie: J.P. Morgan Selects the Top Large-Cap Pharma Stocks to Buy

For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and...

1d ago

J&J announces additional results from pivotal Phase 2b SunRISe-1 study

J&J announces additional results from pivotal Phase 2b SunRISe-1 study

Johnson & Johnson announced additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy...

2d ago

Johnson & Johnson announces new data from Phase 1b/2 OrigAMI-1 study

Johnson & Johnson announces new data from Phase 1b/2 OrigAMI-1 study

Johnson & Johnson announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT combined with chemotherapy...

2d ago

Pfizer presents data from Phase 2 study of ponsegromab in with cancer cachexia

Pfizer presents data from Phase 2 study of ponsegromab in with cancer cachexia

Pfizer announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15, met its...

2d ago

Pfizer announces follow-up results from Phase 2 single-arm PHAROS trial

Pfizer announces follow-up results from Phase 2 single-arm PHAROS trial

Pfizer announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety...

2d ago

Read the latest stock news and analysis from the TipRanks news team.

Recent Analysts Ratings of Healthcare Stocks

Teladoc

Hold

Assigned

2024-09-16

Abbott Laboratories

Buy

Reiterated

2024-09-13

Pfizer

Buy

Reiterated

2024-09-13

Eli Lilly & Co

Buy

Reiterated

2024-09-13

Johnson & Johnson

Hold

Assigned

2024-09-11

UnitedHealth

Buy

Reiterated

2024-09-11

Novartis

Hold

Assigned

2024-09-11

CVS Health

Buy

Assigned

2024-09-04

Roche Holding

Hold

Reiterated

2024-04-08

Eli Lilly & Co

Buy

Initiated

2024-09-13

Most Recent Earnings of Healthcare Stocks

Pfizer

Jul 30, 2024

Jun 01, 2024

0.46 / 0.60

-0.17

Novartis

Jul 18, 2024

Jun 01, 2024

1.85 / 1.97

1.74

Johnson & Johnson

Jul 17, 2024

Jun 01, 2024

2.71 / 2.82

2.66

Roche Holding

Jul 25, 2024

Jun 01, 2024

1.30 / 1.43

1.229

Abbott Laboratories

Jul 18, 2024

Jun 01, 2024

1.10 / 1.14

1.14

Eli Lilly & Co

Aug 08, 2024

Jun 01, 2024

2.74 / 3.92

0.1

CVS Health

Aug 07, 2024

Jun 01, 2024

1.74 / 1.83

2.21

UnitedHealth

Jul 16, 2024

Jun 01, 2024

6.65 / 6.80

6.56

Teladoc

Jul 31, 2024

Jun 01, 2024

-0.34 / -4.92

-0.35

Healthcare Stocks - FAQ

Which Healthcare stocks have a "Strong Buy" analyst rating?

These Healthcare stocks currently have a "Strong Buy" analyst rating consensus:

Abbott Laboratories - Strong Buy, based on 14 analyst ratings, 11 Buy, 3 Hold, and 0 Sell.

Eli Lilly & Co - Strong Buy, based on 20 analyst ratings, 18 Buy, 2 Hold, and 0 Sell.

UnitedHealth - Strong Buy, based on 21 analyst ratings, 21 Buy, 0 Hold, and 0 Sell.

Are Healthcare stocks overpriced?

Pfizer's stock price is currently $30.07, and its average 12-month price target is $32.77.

Novartis's stock price is currently $116.95, and its average 12-month price target is $119.08.

Johnson & Johnson's stock price is currently $166.99, and its average 12-month price target is $172.46.

Roche Holding's stock price is currently $39.21, and its average 12-month price target is $43.00.

Abbott Laboratories's stock price is currently $117.63, and its average 12-month price target is $127.08.

Eli Lilly & Co's stock price is currently $923.54, and its average 12-month price target is $1,039.88.

CVS Health's stock price is currently $58.37, and its average 12-month price target is $64.77.

UnitedHealth's stock price is currently $589.14, and its average 12-month price target is $625.39.

Teladoc's stock price is currently $8.16, and its average 12-month price target is $10.34.

Which Healthcare stocks pay dividends?

Pfizer does not currently pay dividends.

Novartis does not currently pay dividends.

Johnson & Johnson does not currently pay dividends.

Roche Holding does not currently pay dividends.

Abbott Laboratories does not currently pay dividends.

Eli Lilly & Co does not currently pay dividends.

CVS Health does not currently pay dividends.

UnitedHealth does not currently pay dividends.

Teladoc does not currently pay dividends.